PDUFA VI: Industry Ready For 'Hard Sell' To Keep Agreement Intact

Biopharma industry is preparing for the unwelcome possibility that the new Congress and Trump Administration will seek to revisit provisions in the negotiated agreement for the US FDA user fee program's reauthorization.